According to reports Gilead Sciences a top maker of HIV drugs will share its intellectual property... According to reports, Gilead Sciences a top maker of HIV drugs will share its intellectual property... Gilead Sciences Gilead Sciences Bill Wilton is the Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the... Bill Wilton is the Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the... Related Articles The Path to the Cure for Heart Disease: A Cell Signaling Pathway Who’s on First?... Related Articles The Path to the Cure for Heart Disease: A Cell Signaling Pathway Who’s on First?... Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Login to post comments Login to post comments Scott Lazerwith Father and Research Scientist II at Gilead Sciences “I really liked it but I love... Scott Lazerwith Father and Research Scientist II at Gilead Sciences “I really liked it but I love... Growing optimism for Gilead Sciences Inc.’s hepatitis C treatment Sovaldi vaulted shares of the... Growing optimism for Gilead Sciences Inc.’s hepatitis C treatment, Sovaldi, vaulted shares of the... Grade Grade Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Open Collage in a new Window Email the Collage Loading... Image 1 of / 2 Caption Close Image 1 of 2 Image 2 of 2 Gilead Sciences CEO joins billionaires' ranks... Image 1 of / 2 Caption Close Image 1 of 2 Image 2 of 2 Gilead Sciences CEO joins billionaires' ranks... Foto del medicamento Truvada proporcionada por el laboratorio Gilead Sciences. Uncredited AP Tras... Foto del medicamento Truvada proporcionada por el laboratorio Gilead Sciences. Uncredited AP Tras... Werfen Sie einen Exclusivblick auf unser neues Layout. Werfen Sie einen Exclusivblick auf unser neues Layout. Exclusive: HCV Cure - Open Letter to Gilead Sciences Order: Reorder Duration: 2:51 Updated: 04 Jun... Exclusive: HCV Cure - Open Letter to Gilead Sciences Order: Reorder Duration: 2:51 Updated: 04 Jun... John C. Martin CEO of Gilead Sciences a pharmaceutical company has set a price of $1000/pill in... John C. Martin, CEO of Gilead Sciences, a pharmaceutical company, has set a price of $1,000/pill in... Börsengang an der NASDAQ im Januar 1992 Nachdem Gilead Sciences unter der technischen Leitung des... Börsengang an der NASDAQ im Januar 1992 Nachdem Gilead Sciences unter der technischen Leitung des... Dr. Michael Riordan Gilead Sciences founder CEO Chairman interview 1994 Order: Reorder Duration: 3... Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994 Order: Reorder Duration: 3... Stránky farmaceutické firmy Gilead Sciences s níž týmy Antonína Holého dlouhodobě spolupracují... Stránky farmaceutické firmy Gilead Sciences, s níž týmy Antonína Holého dlouhodobě spolupracují... 13. Gilead Sciences Inc. Europe sales: 40 percent Foreign sales: 47 percent Biopharmaceutical... 13. Gilead Sciences Inc. Europe sales: 40 percent Foreign sales: 47 percent Biopharmaceutical... John F. Milligan PhD President and Chief Operating Officer Gilead Sciences Inc. Order: Reorder... John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences, Inc. Order: Reorder... Agrandir PHOTO D'ARCHIVES Agrandir PHOTO D'ARCHIVES Comparte esta información por correo electrónico Comparte esta información por correo electrónico
Próxima »
Pesquisa Avançada